Evolution of decitabine development

Decitabine (5‐aza‐2′‐deoxycytidine) is a hypomethylating agent with a dual mechanism of action: reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses. The original studies in the 1980s used decitabine as a classical anticancer drug, at its maximum clinically tolerated dose, 1500 to 2500 mg/m2 per course. At these doses, decitabine was found to be active in leukemia, but was associated with delayed and prolonged myelosuppression. After a better understanding of epigenetics in cancer and the role of decitabine in epigenetic (hypomethylating) therapy was gained, it was reevaluated at approximately 1/20th of the previous doses (ie, at ‘optimal biologic’ doses that modulate hypomethylation). In these dose schedules of decitabine (100 to 150 mg/m2 per course), the drug was found to be active with manageable side effects in patients with myelodysplastic syndromes (MDS) and other myeloid tumors. Optimizing dosing schedules of decitabine to maximize hypomethylation (low dose, high dose intensity, and multiple cycles) have further improved results, suggesting that decitabine is an active therapy that alters the natural course of MDS. Combination therapies that augment the epigenetic effect of decitabine will likely improve responses and extend its use for the treatment of other malignancies. Cancer 2008. ©2008 American Cancer Society.

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  J. Issa,et al.  Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia , 2007, Cancer.

[3]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[4]  J. Issa,et al.  Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy. , 2006 .

[5]  J. Dipersio,et al.  Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML). , 2006 .

[6]  W. Wilson,et al.  Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST). , 2006 .

[7]  M. Yao,et al.  Quantitative Assessment of Minimal Residual Disease Predicts Outcome of Patients of Acute Myeloid Leukemia with Nucleophosmin (NPM) Mutation. , 2006 .

[8]  H. Kantarjian,et al.  Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61. , 2006 .

[9]  R. Larson,et al.  Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia. , 2006 .

[10]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[11]  Kelly B. Moran,et al.  Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[12]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[13]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[14]  M. Lübbert,et al.  Superiority of prolonged low‐dose azanucleoside administration? , 2006, Cancer.

[15]  B. Dörken,et al.  Decitabine: Where Is the Target?. , 2005 .

[16]  J. Dipersio,et al.  A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). , 2005 .

[17]  R. Schlenk,et al.  Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study. , 2005 .

[18]  M. Grever,et al.  Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity. , 2005 .

[19]  J. Kuykendall.  5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders , 2005, The Annals of pharmacotherapy.

[20]  Heinrich Leonhardt,et al.  Trapped in action: direct visualization of DNA methyltransferase activity in living cells , 2005, Nature Methods.

[21]  R. Momparler.  Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). , 2005, Seminars in hematology.

[22]  Hui Yang,et al.  Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. , 2005, Leukemia research.

[23]  David A Jones,et al.  Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Pazdur,et al.  Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes , 2005, Clinical Cancer Research.

[26]  M. Lübbert,et al.  Re-Treatment with Low-Dose 5-Aza-2′-Deoxycytidine (Decitabine) Results in Second Remissions of Previously Responsive MDS Patients. , 2004 .

[27]  M. Lübbert,et al.  The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. , 2004, Leukemia research.

[28]  C. Froelich,et al.  Human neutrophils lack granzyme A, granzyme B, and perforin. , 2004, Blood.

[29]  R. Lotan,et al.  Hypermethylation and Silencing of the Putative Tumor Suppressor Tazarotene-Induced Gene 1 in Human Cancers , 2004, Cancer Research.

[30]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[31]  G. Schwartsmann,et al.  A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.

[32]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[33]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[34]  R. Claus,et al.  Epigenetic targets in hematopoietic malignancies , 2003, Oncogene.

[35]  Kohzoh Imai,et al.  Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. , 2003, Blood.

[36]  P. Laird,et al.  Phase I trial of continuous infusion 5-aza-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.

[37]  J. Issa,et al.  Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal Cancer , 2003, Molecular and Cellular Biology.

[38]  Peter A. Jones,et al.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[39]  Peter A. Jones,et al.  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.

[40]  Terry L. Smith,et al.  DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  G. Blandino,et al.  Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. , 2002, Blood.

[42]  D. Lavelle,et al.  Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. , 2002, Blood.

[43]  J. Issa,et al.  DNA methylation patterns at relapse in adult acute lymphocytic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[46]  Peter A. Jones,et al.  The Role of DNA Methylation in Mammalian Epigenetics , 2001, Science.

[47]  M. Lübbert,et al.  Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.

[48]  M. Toyota,et al.  Methylation profiling in acute myeloid leukemia. , 2001, Blood.

[49]  J. Issa,et al.  Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.

[50]  P. Jones,et al.  Cancer: Death and methylation , 2001, Nature.

[51]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[52]  R. Hoffman,et al.  2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. , 2000, Blood.

[53]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Clark,et al.  Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. , 1999, Cancer research.

[55]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[56]  B. Quesnel,et al.  Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.

[57]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[58]  K. Bélanger,et al.  Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.

[59]  P. Néve,et al.  Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome , 1997, Leukemia.

[60]  F. Mandelli,et al.  Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. , 1993, Leukemia.

[61]  R. Willemze,et al.  Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. , 1993, Leukemia.

[62]  S. Monfardini,et al.  5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. , 1993, Leukemia.

[63]  V. Zagonel,et al.  5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. , 1993, Leukemia.

[64]  M. van Glabbeke,et al.  The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. , 1987, European journal of cancer & clinical oncology.

[65]  H. Pinedo,et al.  Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. , 1986, Cancer research.

[66]  G. Rivard,et al.  Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. , 1985, Pharmacology & therapeutics.

[67]  N. Onetto,et al.  5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. , 1984, Leukemia research.

[68]  V. L. Wilson,et al.  Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. , 1983, Cancer research.

[69]  G. Rivard,et al.  Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. , 1983, Cancer research.

[70]  J. Christman,et al.  Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.

[71]  Kun-Tsan Lin,et al.  Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. , 1981, Leukemia research.

[72]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[73]  F. Šorm,et al.  Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. , 1968, Neoplasma.